The difference between ensidipine and venetoclax

Enasidenib) and venetoclax (Venetoclax) are both drugs targeted at the treatment of specific types of leukemia, but they differ in their mechanisms of action, indications, side effects, and clinical applications. The following is a detailed comparison of the differences between these two drugs:

1. Mechanism of action:

Ensidipine: Ensidipine is an IDH2 (isomeric cysteine synthase 2) inhibitor, mainly used to treat acute myeloid leukemia (AML) carrying IDH2 gene mutations. It blocks the growth and proliferation of leukemia cells by inhibiting the abnormal enzyme activity caused by IDH2 gene mutations.

Venetoclax: Venetoclax is a BCL-2 (Bcellular lymphoma-2) inhibitor, mainly used to treat patients with chronic lymphocytic leukemia (CLL) and AML. By inhibiting the BCL-2 protein, it destroys the apoptosis (cell self-destruction) inhibitory mechanism in leukemia cells, prompting leukemia cells to undergo apoptosis and die.

2. Indications:

Ensidipine: Ensidipine is mainly suitable for the treatment of AML patients carrying IDH2 gene mutations. This gene mutation is common in some patients with AML.

Venetoclax: Venetoclax is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) and AML. It is also used in the treatment of some other types of leukemia and lymphoma.

3. Side effects:

Ensidipine: Ensidipine may cause some common side effects, including nausea, vomiting, diarrhea, fatigue, headache, muscle pain, etc. In addition, it may cause serious adverse reactions such as abnormal liver function, bleeding tendency, and electrocardiogram changes.

Venetoclax: Common side effects of venetoclax include nausea, vomiting, diarrhea, fatigue, headache and other digestive system and general discomfort symptoms. It may also cause severe cytolytic reactions (including abnormal liver function, abnormal renal function, hypotension, etc.) and nervous system toxicity (including peripheral neuritis, dizziness, etc.).

4. Clinical application:

Ensidipine: Ensidipine is commonly used as monotherapy in patients with AML, especially those who carry mutations in the IDH2 gene. It has been FDAapproved to treat relapsed or refractory AML.

Venetoclax: Venetoclax is often used in combination with other drugs to treat chronic lymphocytic leukemia (CLL) and AML. It is often used in combination with the anti-cancer drugs Fludarabine (Fludarabine), cyclophosphamide (Cyclophosphamide), etc., or with low-dose retinoic acid (All-trans retinoic acid, ATRA) and other AML therapeutic drugs are used in combination.

5. Price and Availability:

Ensidipine: Ensidipine is a newer drug and is relatively expensive. It may not be readily available and may be limited by health insurance coverage. Ensidipine is not currently on the market in China, so patients cannot purchase encidipine domestically and need to purchase encidipine through overseas channels. The cheaper ones abroad are generic drugs, especially the Laos version and the Bangladeshi version. The price ranges from more than 2,000 yuan to more than 4,000 yuan, and the ingredients of the original drugs and generic drugs are basically the same.

Venetoclax: Venetoclax has been used clinically for many years and is therefore more commonly available and easier to obtain. The price is relatively high, but some or all of the cost can often be paid for through health insurance coverage.

To sum up, ensidipine and venetoclax are two drugs for the treatment of leukemia. Although they both play a role in the treatment of specific types of leukemia, there are some differences in their mechanisms of action, indications, side effects, clinical applications, price and availability. When choosing treatment drugs, patients should make comprehensive considerations based on their doctor's recommendations and individual circumstances.